Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

New England Journal of Medicine

Volumn 375, Issue 19, 2016, Pages 1823-1833

  Reck, Martin ^a   Rodriguez Abreu, Delvys ^b   Robinson, Andrew G ^c   Hui, Rina ^d   Csöszi, Tibor ^f   Fülöp, Andrea ^g   Gottfried, Maya ^h   Peled, Nir ⁱ   Tafreshi, Ali ^e   Cuffe, Sinead ^j   O'Brien, Mary ^k   Rao, Suman ^l   Hotta, Katsuyuki ⁿ   Leiby, Melanie A ^o   Lubiniecki, Gregory M ^o   Shentu, Yue ^o   Rangwala, Reshma ^o   Brahmer, Julie R ^m  

^a Mitglied im DZL   (Germany)

^b HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^c KINGSTON GENERAL HOSPITAL   (Canada)

^d UNIVERSITY OF SYDNEY   (Australia)

^e Southern Medical Day Care Centre   (Australia)

^f Jász Nagykun Szolnok County Hospital   (Hungary)

^g Orszagos Koranyi Tbc es Pulmonologiai Intezet   (Hungary)

^h MEIR MEDICAL CENTER   (Israel)

ⁱ TEL AVIV UNIVERSITY   (Israel)

^j ST JAMES S HOSPITAL   (Ireland)

^k ROYAL MARSDEN HOSPITAL   (United Kingdom)

^l Department of Pediatrics   (United States)

^m JOHNS HOPKINS UNIVERSITY   (United States)

ⁿ OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^o MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CISPLATIN; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; PACLITAXEL; PEMBROLIZUMAB; PEMETREXED; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PLATINUM DERIVATIVE; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ANAPLASTIC LYMPHOMA KINASE GENE; ANEMIA; ARTICLE; CANCER CELL; CANCER GROWTH; COLITIS; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DECREASED APPETITE; DIARRHEA; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; FEVER; GENE MUTATION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; INFUSION RELATED REACTION; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYOSITIS; NAUSEA; NEPHRITIS; NEUTROPENIA; NEUTROPHIL COUNT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PANCREATITIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THYROIDITIS; VOMITING; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; COMPARATIVE STUDY; INTENTION TO TREAT ANALYSIS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLATINUM COMPOUNDS; PROGRAMMED CELL DEATH 1 RECEPTOR; SURVIVAL ANALYSIS;

EID: 84994802263     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1606774     Document Type: Article

References (16)

1. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced nonsmall- cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016; 387: 1540-50.
2. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non- small-cell lung cancer. N Engl J Med 2015; 372: 2018-28.
3. Chatterjee M, Turner DC, Felip E, et al. Systematic evaluation of pembrolizumab dosing in patients with advanced nonsmall- cell lung cancer. Ann Oncol 2016; 27: 1291-8.
4. Hui R, Gandhi L, Carcereny E, et al. Long-Term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro). J Clin Oncol 2016; 34(15 Suppl): 9026. abstract.
5. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
6. PD-L1 IHC 22C3 pharm Dx. Carpinteria, CA: Dako North America, 2015 (package insert).
7. Roach C, Zhang N, Corigliano E, et al. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol 2016; 24: 392-7.
8. Pilkington G, Boland A, Brown T, Oyee J, Bagust A, Dickson R. A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic nonsmall cell lung cancer. Thorax 2015; 70: 359-67.
9. Tan PS, Lopes G, Acharyya S, Bilger M, Haaland B. Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: results by performance status, EGFR mutation, histology and response to previous induction. Eur J Cancer 2015; 51: 2330-44.
10. Xiao HQ, Tian RH, Zhang ZH, Du KQ, Ni YM. Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: A systematic review and meta-Analysis. Onco Targets Ther 2016; 9: 1471-6.
11. Freshwater T, Stone J, de Greef R, et al. Assessment of pembrolizumab (MK-3475) dosing strategy based on population pharmacokinetics and exposure-response models. Presented at the 6th American Conference on Pharmacometrics, Arlington, VA, October 3-7, 2015.
12. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16: 908-18.
13. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-32.
14. Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial. Lancet Oncol 2016; 17: 717- 26.
15. Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 2016; 34: 2460-7.
16. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol 2016; 17: 956-65.